1. Home
  2. Analysis
  3. Depakene
  4. Dolutegravir

Depakene and Dolutegravir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Depakene (valproic acid) and Dolutegravir (dolutegravir). Common drug interactions include hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Depakene and Dolutegravir. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

What is Dolutegravir?

Dolutegravir has active ingredients of dolutegravir. eHealthMe is studying from 7,071 Dolutegravir users. Check the latest studies of Dolutegravir.

On Jul, 10, 2026

11 people who take Depakene and Dolutegravir together, and have interactions are studied.

Depakene and Dolutegravir drug interactions.

What are the common drug interactions of Depakene and Dolutegravir, by gender? *:

female:

n/a

male:

  1. Hypertension (high blood pressure)
  2. Hypertriglyceridaemia (excess of triglycerides in the blood)
  3. Type 2 diabetes mellitus
  4. Dermal cyst
  5. Fibula fracture

What are the common drug interactions of Depakene and Dolutegravir, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Hypertension (high blood pressure)
  2. Hypertriglyceridaemia (excess of triglycerides in the blood)
  3. Type 2 diabetes mellitus
  4. Dermal cyst
  5. Fibula fracture

50-59:

  1. Hypertension (high blood pressure)
  2. Hypertriglyceridaemia (excess of triglycerides in the blood)
  3. Type 2 diabetes mellitus

60+:

n/a

What are the existing conditions these people have? *

  1. Hiv Infection: 11 people, 100.00%
  2. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 10 people, 90.91%
  3. Asthma: 10 people, 90.91%
  4. Diabetes: 8 people, 72.73%
  5. Stress And Anxiety: 1 person, 9.09%
  6. Depression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and Dolutegravir?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Depakene and Dolutegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Dolutegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Depakene and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dolutegravir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid and dolutegravir (the active ingredients of Depakene and Dolutegravir, respectively), and Depakene and Dolutegravir (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.